Category: Top Story
-
Micron Advances on Early HBM4 Shipments, Reassures on Product Quality
Micron Technology (NASDAQ:MU) moved higher after executives signaled that volume shipments of its next-generation HBM4 memory have begun earlier than previously indicated. Speaking at Wolfe Research’s Autos/Semis conference on Wednesday, Micron’s leadership team — including CFO Mark Murphy — addressed market speculation around potential technical issues with its HBM4 chips. Management said the company now…
-
Restaurant Brands Tops Q4 Estimates on International Burger King Strength
Restaurant Brands International (NYSE:QSR) reported fourth-quarter results that outpaced market expectations, fueled by solid international momentum at Burger King. System-wide comparable sales rose 3.1% in the quarter, improving from 2.5% a year earlier and beating Bloomberg consensus forecasts for 2.55% growth. On an adjusted basis, earnings per share reached $0.96 for the quarter ended December…
-
McDonald’s Beats on Revenue as Value Offers Lift Comparable Sales
McDonald’s Corporation (NYSE:MCD) posted fourth-quarter revenue ahead of Wall Street forecasts, supported by robust comparable sales growth across its global footprint as the chain leaned into promotions and value menus to attract price-sensitive consumers. Shares of the fast-food group edged slightly lower in premarket trading on Thursday, despite the stronger-than-expected top-line performance. Revenue for the…
-
FTC Questions Apple News Over Claims of Political Bias
Apple Inc (NASDAQ:AAPL) is facing scrutiny from the U.S. Federal Trade Commission following allegations that its Apple News platform favors left-leaning outlets while limiting visibility for conservative publications. FTC Chairman Andrew Ferguson said in a post on X that he had written to Apple CEO Tim Cook, warning that the company could be breaching FTC…
-
Cisco Drops in Premarket as Higher Memory Costs Pressure Margins
Cisco Systems (NASDAQ:CSCO) shares fell in premarket U.S. trading Thursday after the networking heavyweight reported a quarterly gross margin that came in below Wall Street expectations. A member of the Dow Jones Industrial Average, Cisco supplies a broad portfolio of networking products and services—from routers and switches to wireless access points and controllers—used by enterprises…
-
Futures Edge Higher After Jobs Shock; Cisco Drops on Margin Miss: Dow Jones, S&P, Nasdaq, Wall Street
U.S. equity futures pointed to a firmer open on Thursday as investors digested the fallout from a surprisingly strong January jobs report and shifted their attention toward fresh earnings releases and upcoming inflation data. By 03:01 ET, Dow futures were up 143 points, or 0.3%, S&P 500 futures had gained 0.3%, and Nasdaq 100 futures…
-
U.S. Stocks Close Modestly Lower As Early Buying Interest Fades
After failing to sustain an initial move to the upside, stocks quickly gave back ground in early trading on Wednesday and showed a lack of direction over the remainder of the session. The major averages spent the day bouncing back and forth across the unchanged line before eventually closing modestly lower. The Dow slipped 66.74…
-
T-Mobile tops Q4 estimates, shares edge lower
T-Mobile US, Inc. (NASDAQ:TMUS) delivered fourth-quarter results ahead of Wall Street expectations on Wednesday, but its shares slipped 1.5% following the release. The wireless carrier reported adjusted earnings per share of $2.14, beating the consensus forecast of $2.04. Quarterly revenue rose 11.3% year over year to $24.33 billion, exceeding analyst estimates of $24.18 billion and…
-
Kraft Heinz slides as 2026 outlook disappoints despite Q4 earnings beat
Kraft Heinz (NASDAQ:KHC) shares dropped 6.3% on Wednesday after the packaged food maker topped fourth-quarter profit expectations but delivered a weaker-than-anticipated outlook for fiscal 2026, alongside plans for a $600 million push to reignite growth. For the fourth quarter, the company posted adjusted earnings of $0.67 per share, ahead of the $0.61 analysts had forecast.…
-
FDA clears Merck’s KEYTRUDA and KEYTRUDA QLEX for platinum-resistant ovarian cancer
The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors express PD-L1, the company said Monday. The authorization applies to…